Changes in magnetic resonance mammography due to hormone replacement therapy

Breast Cancer Research

Werner A Kaiser¹  Susanne Wurdinger¹  Ansgar Malich¹  Christiane Marx¹  Dieter Sauner¹  Steffen Sachse¹  Stefan OR Pfleiderer¹ 

[1] Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller-University, Jena, Germany

关键词: magnetic resonance imaging;    hormone replacement therapy;    ductal carcinoma in situ;    breast cancer;    breast;   

 received in 2003-11-19, accepted in 2004-02-24,  发布年份 2004

【 摘 要 】

Background

The aim of the present article is to investigate effects of hormone replacement therapy (HRT) on contrast medium enhancement patterns in postmenopausal patients during magnetic resonance mammography (MRM).

Materials and methods

Two hundred and fifteen patients receiving hormonal medication were divided into four groups: 150 patients with 1 MRM during HRT (group A), 13 patients with 2 MRMs under HRT (group B), 30 patients with 1 MRM during HRT and 1 MRM after HRT withdrawal (group C), and 22 women with 1 MRM after HRT withdrawal (group D). Dynamic MRM was performed at 1.5 Tesla. Signal intensity changes were characterized by five time curves: minimal enhancement (type I), weak continuous enhancement (type II), strong continuous enhancement (type III), and a steep initial slope followed by a plateau phenomenon (type IV) or a washout effect (type V).

Results

Of all 193 patients under HRT (group A + group B + group C), 60 patients (31.1%) showed curve type I, 88 patients (45.6%) showed type II and 45 patients (23.3%) showed type III. There were significant differences to 52 patients after HRT withdrawal (group C + group D) (P < 0.0001), with 42 patients (80.8%) for curve type I, 8 patients (15.4%) for type II, and 2 patients (3.8%) for type III. In both MRM sessions in group B, 69% of the patients showed identical curve types without significant differences (P = 0.375). In group C, 28 of 30 patients (93%) dropped to lower curve types with significant differences in curve types during and after HRT (P < 0.0001).

Conclusion

The majority of patients receiving postmenopausal HRT showed bilateral symmetrical, continuous enhancement without evidence of a plateau phenomenon or a washout effect due to HRT in MRM. Hormonal effects could be proven and were reproducible and reversible.

【 授权许可】

   
2004 Pfleiderer et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Gibaldi M: Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J Clin Pharmacol 1997, 37:1087-1099.
• [2]Lindsay R: Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993, 95:37S-39S.
• [3]Stampfer M, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurse's Health Study. N Engl J Med 1991, 325:1758-1766.
• [4]Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE: The primary prevention of coronary heart disease in women. N Engl J Med 1995, 332:1758-1766.
• [5]Grimes DA, Lobo RA: Perspectives on the Women's Health Initiative trial of hormonal replacement therapy. Obstet Gynecol 2002, 100:1344-1353.
• [6]Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R: Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002, 95:2455-2465.
• [7]Persson I, Thurfjell E, Bergstrom R, Holmberg L: Hormone replacement therapy and the risk of breast cancer. Nested case–control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997, 72:758-761.
• [8]Harvey JA, Pinkerton JV, Herman CR: Short-term cessation of hormone replacement therapy and improvement in mammographic specificity. J Natl Cancer Inst 1997, 89:1623-1625.
• [9]Vachon CM, Sellers TA, Vierkant RA, Wu FF, Brandt KR: Case–control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiol Biomarkers Prev 2002, 11:1382-1388.
• [10]Litherland JC, Stallard S, Hole D, Cordiner C: The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 1999, 54:285-288.
• [11]Banks E: Hormone replacement therapy and the sensitivity and specificity of breast cancer screening. a review. J Med Screen 2001, 8:29-34.
• [12]Marugg RC, van der Mooren MJ, Hendriks JH, Holland R, Ruijs SH: Mammographic changes in postmenopausal women on Hormone replacement therapy. Eur Radiol 1997, 7:749-755.
• [13]Ozdemir A, Konus O, Nas T, Erbas G, Cosar S, Isik S: Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynecol Obstet 1999, 67:23-32.
• [14]Germer U, Tetzlaff A, Geipel A, Diedrich K, Gembruch U: Strong impact of estrogen environment on Doppler variables used for differentiation between benign and malignant breast lesions. Ultrasound Obstet Gynecol 2002, 19:380-385.
• [15]Nelson TR, Pretorius DH, Schiffer LM: Menstrual variation of normal breast NMR relaxation parameters. J Comput Assist Tomogr 1985, 9:875-879.
• [16]Martin B, El Yousef SJ: Transverse relaxation time values in MR imaging of normal breast during menstrual cycle. J Comput Assist Tomogr 1986, 10:924-927.
• [17]Rieber A, Nüssle K, Merckle E, Kreienberg R, Tomczak R, Brambs HJ: MR mammography. influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease. Eur Radiol 1999, 9:1107-1112.
• [18]Müller-Schimpfle M, Ohmenhausen K, Stoll P, Dietz K, Claussen CD: Menstrual cycle and age. influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997, 203:145-149.
• [19]Heywang-Köbrunner SH, Viehweg P, Heinig A, Küchler C: Contrast-enhanced MR imaging of the breast. accuracy, value, controversies, solutions. Eur J Radiol 1997, 24:94-108.
• [20]Hussain Z, Roberts N, Whitehouse GH, Garcia-Finana M, Percy D: Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. Br J Radiol 1999, 72:236-245.
• [21]Reichenbach JR, Przetak C, Klinger G, Kaiser WA: Assessment of breast tissue changes on hormonal replacement therapy using MRI. a pilot study. J Comput Assist Tomogr 1999, 23:407-413.
• [22]Kaiser WA, Zeitler E: MR-imaging of the breast: fast imaging sequences with and without Gd-DTPA. Radiology 1989, 170:681-686.
• [23]Graham SJ, Stanchev PL, Lloyd-Smith CO, Bronskill MJ, Plewes DB: Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 1995, 5:695-701.
• [24]Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA: Lobular carcinoma in situ of the female breast. Am J Surg Pathol 1993, 17:14-21.
• [25]Neubauer H, Li M, Kuehne-Heid R, Schneider A, Kaiser WA: High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography. characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol 2003, 76:3-12.
• [26]Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N: MR imaging of tumor microcirculation. promise for the new millennium. J Magn Reson Imaging 1999, 10:903-907.
• [27]Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15:17-35.
• [28]Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC: Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994, 86:431-436.
• [29]Fowler PA, Casey CE, Cameron GG, Foster MA, Knight CH: Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging. Br J Obstet Gynecol 1990, 97:595-602.
• [30]Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lutterbey G, Schild HH: Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast. Normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997, 203:137-144.
• [31]Bogin L, Degani H: Hormonal regulation in orthotopic MCF7 human breast cancer. Cancer Res 2002, 62:1948-1951.